Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 1/20 | 0.54 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | ERCC5 | P28715 | 2/20 | 0.44 |
| ▸ | FEN1 | P39748 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787118 | 0.83 | AKR1C2 (0.70) | AKR1C2AKR1C1LMNAALDH1A1ERCC5 | |
| SCHEMBL844384 | 0.82 | MEN1 (0.54) | KMT2AMEN1LMNASMN1; SMN2MAPT | |
| SCHEMBL13525215 | 0.82 | ALDH1A1 (0.53) | AKR1C2AKR1C1KMT2AMEN1MAPT | |
| SCHEMBL28113573 | 0.81 | AKR1C2 (0.56) | AKR1C2AKR1C1LMNASMN1; SMN2CNR1 | |
| SCHEMBL787287 | 0.80 | CYP4F2 (0.59) | KMT2AMEN1LMNASMN1; SMN2MAPT | |
| SCHEMBL31350062 | 0.80 | MEN1 (0.49) | KMT2AMEN1LMNASMN1; SMN2MAPT | |
| SCHEMBL31350078 | 0.80 | MEN1 (0.49) | KMT2AMEN1LMNASMN1; SMN2MAPT | |
| SCHEMBL31312075 | 0.80 | CYP4F2 (0.59) | KMT2AMEN1LMNASMN1; SMN2MAPT | |
| SCHEMBL31298127 | 0.78 | EGFR (0.60) | SMN1; SMN2MAPTKDM4EALDH1A1TSHR | |
| SCHEMBL6138470 | 0.78 | EGFR (0.60) | SMN1; SMN2MAPTKDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025006553-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024263563-A1 | METABOTROPIC GLUTAMATE SUBTYPE-2 AND -3 RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-12-26 | — | — | WO | disclosed |
| US-8748632-B2 | Positive allosteric modulators of group II mGluRs | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2011116356-A2 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | GRM2, GRM1, GRIN2C | AKR1C2 4832/4885AKR1C1 4866/4885KMT2A 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.